Which has higher earnings & valuation, ANL or PMN?

Adlai Nortye has higher revenue and earnings than Promis Neurosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adlai Nortye $5M 75.92 -$35.53M N/A N/A Promis Neurosciences N/A N/A -$39.72M -$14.51 N/A

Is ANL or PMN more profitable?

Adlai Nortye's return on equity of 0.00% beat Promis Neurosciences' return on equity. Company Net Margins Return on Equity Return on Assets Adlai Nortye N/A N/A N/A Promis Neurosciences N/A -237.99% -151.04%

Which has stronger valuation and earnings, PMN or BNTC?

Benitec Biopharma is trading at a lower price-to-earnings ratio than Promis Neurosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Promis Neurosciences N/A N/A -$39.72M -$14.51 N/A Benitec Biopharma N/A N/A -$37.92M -$1.14 N/A

Is PMN or BNTC more profitable?

Benitec Biopharma's return on equity of -34.82% beat Promis Neurosciences' return on equity. Company Net Margins Return on Equity Return on Assets Promis Neurosciences N/A -237.99% -151.04% Benitec Biopharma N/A -34.82% -34.11%

Does the media favor PMN or BNTC?

In the previous week, Promis Neurosciences and Promis Neurosciences both had 1 articles in the media. Promis Neurosciences' average media sentiment score of 0.50 beat Benitec Biopharma's score of -0.54 indicating that Promis Neurosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Promis Neurosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Benitec Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative

Is EOLS or PMN more profitable?

Promis Neurosciences has a net margin of 0.00% compared to Evolus' net margin of -14.39%. Evolus' return on equity of 0.00% beat Promis Neurosciences' return on equity. Company Net Margins Return on Equity Return on Assets Evolus -14.39% N/A -19.03% Promis Neurosciences N/A -237.99% -151.04%

Is PMN or IPSC more profitable?

Century Therapeutics' return on equity of -49.89% beat Promis Neurosciences' return on equity. Company Net Margins Return on Equity Return on Assets Promis Neurosciences N/A -237.99% -151.04% Century Therapeutics N/A -49.89% -37.42%

Does the media prefer XFOR or PMN?

In the previous week, X4 Pharmaceuticals had 4 more articles in the media than Promis Neurosciences. MarketBeat recorded 5 mentions for X4 Pharmaceuticals and 1 mentions for Promis Neurosciences. Promis Neurosciences' average media sentiment score of 0.50 beat X4 Pharmaceuticals' score of 0.17 indicating that Promis Neurosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment X4 Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Promis Neurosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Promis Neurosciences (PMN) Competitors

$13.35 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$13.48 +0.13 (+0.94%)

As of 07/2/2026 06:32 PM Eastern

Compare

PMN vs. ANL, BNTC, EOLS, IPSC, and XFOR

Should you buy Promis Neurosciences stock or one of its competitors? MarketBeat compares Promis Neurosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Promis Neurosciences include Adlai Nortye (ANL), Benitec Biopharma (BNTC), Evolus (EOLS), Century Therapeutics (IPSC), and X4 Pharmaceuticals (XFOR). These companies are all part of the "pharmaceutical products" industry.

How does Promis Neurosciences compare to Adlai Nortye?

Adlai Nortye (NASDAQ:ANL) and Promis Neurosciences (NASDAQ:PMN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, risk, profitability, valuation and earnings.

Adlai Nortye has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market. Comparatively, Promis Neurosciences has a beta of -0.23, meaning that its stock price is 123% less volatile than the broader market.

Adlai Nortye presently has a consensus target price of $24.25, suggesting a potential upside of 155.53%. Promis Neurosciences has a consensus target price of $26.50, suggesting a potential upside of 98.50%. Given Adlai Nortye's higher possible upside, equities research analysts clearly believe Adlai Nortye is more favorable than Promis Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Promis Neurosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Adlai Nortye has higher revenue and earnings than Promis Neurosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adlai Nortye	$5M	75.92	-$35.53M	N/A	N/A
Promis Neurosciences	N/A	N/A	-$39.72M	-$14.51	N/A

In the previous week, Promis Neurosciences had 1 more articles in the media than Adlai Nortye. MarketBeat recorded 1 mentions for Promis Neurosciences and 0 mentions for Adlai Nortye. Promis Neurosciences' average media sentiment score of 0.50 beat Adlai Nortye's score of 0.00 indicating that Promis Neurosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Adlai Nortye	Neutral
Promis Neurosciences	Positive

Adlai Nortye's return on equity of 0.00% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adlai Nortye	N/A	N/A	N/A
Promis Neurosciences	N/A	-237.99%	-151.04%

35.2% of Adlai Nortye shares are owned by institutional investors. Comparatively, 50.1% of Promis Neurosciences shares are owned by institutional investors. 1.5% of Promis Neurosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Adlai Nortye beats Promis Neurosciences on 7 of the 12 factors compared between the two stocks.

How does Promis Neurosciences compare to Benitec Biopharma?

Promis Neurosciences (NASDAQ:PMN) and Benitec Biopharma (NASDAQ:BNTC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk.

Benitec Biopharma is trading at a lower price-to-earnings ratio than Promis Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Promis Neurosciences	N/A	N/A	-$39.72M	-$14.51	N/A
Benitec Biopharma	N/A	N/A	-$37.92M	-$1.14	N/A

In the previous week, Promis Neurosciences and Promis Neurosciences both had 1 articles in the media. Promis Neurosciences' average media sentiment score of 0.50 beat Benitec Biopharma's score of -0.54 indicating that Promis Neurosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Promis Neurosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Benitec Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Benitec Biopharma's return on equity of -34.82% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Promis Neurosciences	N/A	-237.99%	-151.04%
Benitec Biopharma	N/A	-34.82%	-34.11%

Promis Neurosciences presently has a consensus price target of $26.50, suggesting a potential upside of 98.50%. Benitec Biopharma has a consensus price target of $27.00, suggesting a potential upside of 104.24%. Given Benitec Biopharma's higher probable upside, analysts plainly believe Benitec Biopharma is more favorable than Promis Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Promis Neurosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Benitec Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

50.1% of Promis Neurosciences shares are held by institutional investors. Comparatively, 52.2% of Benitec Biopharma shares are held by institutional investors. 1.5% of Promis Neurosciences shares are held by insiders. Comparatively, 4.8% of Benitec Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Promis Neurosciences has a beta of -0.23, meaning that its stock price is 123% less volatile than the broader market. Comparatively, Benitec Biopharma has a beta of 0.25, meaning that its stock price is 75% less volatile than the broader market.

Summary

Benitec Biopharma beats Promis Neurosciences on 9 of the 13 factors compared between the two stocks.

How does Promis Neurosciences compare to Evolus?

Evolus (NASDAQ:EOLS) and Promis Neurosciences (NASDAQ:PMN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

Evolus currently has a consensus target price of $16.00, suggesting a potential upside of 131.88%. Promis Neurosciences has a consensus target price of $26.50, suggesting a potential upside of 98.50%. Given Evolus' higher probable upside, equities research analysts plainly believe Evolus is more favorable than Promis Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evolus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Promis Neurosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, Promis Neurosciences had 1 more articles in the media than Evolus. MarketBeat recorded 1 mentions for Promis Neurosciences and 0 mentions for Evolus. Promis Neurosciences' average media sentiment score of 0.50 beat Evolus' score of 0.00 indicating that Promis Neurosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Evolus	Neutral
Promis Neurosciences	Positive

Promis Neurosciences has lower revenue, but higher earnings than Evolus. Evolus is trading at a lower price-to-earnings ratio than Promis Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evolus	$297.18M	1.53	-$51.64M	-$0.67	N/A
Promis Neurosciences	N/A	N/A	-$39.72M	-$14.51	N/A

Promis Neurosciences has a net margin of 0.00% compared to Evolus' net margin of -14.39%. Evolus' return on equity of 0.00% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evolus	-14.39%	N/A	-19.03%
Promis Neurosciences	N/A	-237.99%	-151.04%

90.7% of Evolus shares are held by institutional investors. Comparatively, 50.1% of Promis Neurosciences shares are held by institutional investors. 5.0% of Evolus shares are held by company insiders. Comparatively, 1.5% of Promis Neurosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Evolus has a beta of 1.32, indicating that its share price is 32% more volatile than the broader market. Comparatively, Promis Neurosciences has a beta of -0.23, indicating that its share price is 123% less volatile than the broader market.

Summary

Evolus beats Promis Neurosciences on 9 of the 16 factors compared between the two stocks.

How does Promis Neurosciences compare to Century Therapeutics?

Promis Neurosciences (NASDAQ:PMN) and Century Therapeutics (NASDAQ:IPSC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings, dividends and media sentiment.

Promis Neurosciences currently has a consensus price target of $26.50, suggesting a potential upside of 98.50%. Century Therapeutics has a consensus price target of $4.75, suggesting a potential upside of 95.47%. Given Promis Neurosciences' stronger consensus rating and higher possible upside, analysts clearly believe Promis Neurosciences is more favorable than Century Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Promis Neurosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

50.1% of Promis Neurosciences shares are owned by institutional investors. Comparatively, 50.2% of Century Therapeutics shares are owned by institutional investors. 1.5% of Promis Neurosciences shares are owned by insiders. Comparatively, 2.4% of Century Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Promis Neurosciences had 1 more articles in the media than Century Therapeutics. MarketBeat recorded 1 mentions for Promis Neurosciences and 0 mentions for Century Therapeutics. Promis Neurosciences' average media sentiment score of 0.50 beat Century Therapeutics' score of -0.63 indicating that Promis Neurosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Promis Neurosciences	Positive
Century Therapeutics	Negative

Promis Neurosciences has a beta of -0.23, indicating that its share price is 123% less volatile than the broader market. Comparatively, Century Therapeutics has a beta of 1.55, indicating that its share price is 55% more volatile than the broader market.

Century Therapeutics has higher revenue and earnings than Promis Neurosciences. Century Therapeutics is trading at a lower price-to-earnings ratio than Promis Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Promis Neurosciences	N/A	N/A	-$39.72M	-$14.51	N/A
Century Therapeutics	$109.16M	4.01	-$9.58M	-$1.14	N/A

Century Therapeutics' return on equity of -49.89% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Promis Neurosciences	N/A	-237.99%	-151.04%
Century Therapeutics	N/A	-49.89%	-37.42%

Summary

Century Therapeutics beats Promis Neurosciences on 9 of the 15 factors compared between the two stocks.

How does Promis Neurosciences compare to X4 Pharmaceuticals?

X4 Pharmaceuticals (NASDAQ:XFOR) and Promis Neurosciences (NASDAQ:PMN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk, media sentiment and earnings.

In the previous week, X4 Pharmaceuticals had 4 more articles in the media than Promis Neurosciences. MarketBeat recorded 5 mentions for X4 Pharmaceuticals and 1 mentions for Promis Neurosciences. Promis Neurosciences' average media sentiment score of 0.50 beat X4 Pharmaceuticals' score of 0.17 indicating that Promis Neurosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
X4 Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Promis Neurosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

X4 Pharmaceuticals currently has a consensus price target of $9.38, suggesting a potential upside of 127.00%. Promis Neurosciences has a consensus price target of $26.50, suggesting a potential upside of 98.50%. Given X4 Pharmaceuticals' higher possible upside, research analysts clearly believe X4 Pharmaceuticals is more favorable than Promis Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Promis Neurosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Promis Neurosciences has lower revenue, but higher earnings than X4 Pharmaceuticals. Promis Neurosciences is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
X4 Pharmaceuticals	$35.11M	11.09	-$79.20M	-$4.54	N/A
Promis Neurosciences	N/A	N/A	-$39.72M	-$14.51	N/A

Promis Neurosciences has a net margin of 0.00% compared to X4 Pharmaceuticals' net margin of -1,106.30%. X4 Pharmaceuticals' return on equity of -94.90% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
X4 Pharmaceuticals	-1,106.30%	-94.90%	-48.09%
Promis Neurosciences	N/A	-237.99%	-151.04%

X4 Pharmaceuticals has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market. Comparatively, Promis Neurosciences has a beta of -0.23, meaning that its share price is 123% less volatile than the broader market.

72.0% of X4 Pharmaceuticals shares are held by institutional investors. Comparatively, 50.1% of Promis Neurosciences shares are held by institutional investors. 1.1% of X4 Pharmaceuticals shares are held by company insiders. Comparatively, 1.5% of Promis Neurosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

X4 Pharmaceuticals beats Promis Neurosciences on 10 of the 16 factors compared between the two stocks.

Get Promis Neurosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PMN vs. The Competition

Export

Metric	Promis Neurosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$119.72M	$3.78B	$7.18B	$12.47B
Dividend Yield	N/A	2.16%	2.67%	6.50%
P/E Ratio	-0.92	21.61	28.02	24.70
Price / Sales	N/A	325.90	532.59	98.61
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	-23.02	8.66	10.96	6.46
Net Income	-$39.72M	$23.81M	$3.57B	$337.01M
7 Day Performance	26.78%	3.39%	2.12%	1.69%
1 Month Performance	46.22%	10.81%	5.25%	3.81%
1 Year Performance	15.33%	62.61%	33.29%	23.90%

Promis Neurosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PMN Promis Neurosciences	3.713 of 5 stars	$13.35 flat	$26.50 +98.5%	+15.3%	$119.72M	N/A	N/A	5	Analyst Forecast Gap Up
ANL Adlai Nortye	1.5337 of 5 stars	$10.60 -7.8%	$24.25 +128.8%	+506.0%	$460M	$5M	N/A	127
BNTC Benitec Biopharma	1.5032 of 5 stars	$12.69 -5.2%	$27.00 +112.8%	+0.6%	$459.66M	N/A	N/A	20	News Coverage Positive News
EOLS Evolus	2.073 of 5 stars	$6.76 -2.6%	$16.00 +136.7%	-25.6%	$457.03M	$297.18M	N/A	170	Positive News
IPSC Century Therapeutics	1.5731 of 5 stars	$2.39 -2.4%	$4.75 +98.7%	+333.9%	$441.87M	$109.16M	N/A	170

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PMN) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Promis Neurosciences (PMN) Competitors

PMN vs. ANL, BNTC, EOLS, IPSC, and XFOR

How does Promis Neurosciences compare to Adlai Nortye?

Summary

How does Promis Neurosciences compare to Benitec Biopharma?

Summary

How does Promis Neurosciences compare to Evolus?

Summary

How does Promis Neurosciences compare to Century Therapeutics?

Summary

How does Promis Neurosciences compare to X4 Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMN vs. The Competition

Promis Neurosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Promis Neurosciences (PMN) Competitors

PMN vs. ANL, BNTC, EOLS, IPSC, and XFOR

How does Promis Neurosciences compare to Adlai Nortye?

Which has more risk and volatility, ANL or PMN?

Do analysts prefer ANL or PMN?

Which has higher earnings & valuation, ANL or PMN?

Does the media prefer ANL or PMN?

Is ANL or PMN more profitable?

Do institutionals & insiders have more ownership in ANL or PMN?

Summary

How does Promis Neurosciences compare to Benitec Biopharma?

Which has stronger valuation and earnings, PMN or BNTC?

Does the media favor PMN or BNTC?

Is PMN or BNTC more profitable?

Do analysts recommend PMN or BNTC?

Do institutionals and insiders hold more shares of PMN or BNTC?

Which has more volatility & risk, PMN or BNTC?

Summary

How does Promis Neurosciences compare to Evolus?

Do analysts recommend EOLS or PMN?

Does the media prefer EOLS or PMN?

Which has preferable earnings & valuation, EOLS or PMN?

Is EOLS or PMN more profitable?

Do institutionals & insiders have more ownership in EOLS or PMN?

Which has more volatility and risk, EOLS or PMN?

Summary

How does Promis Neurosciences compare to Century Therapeutics?

Do analysts rate PMN or IPSC?

Do insiders & institutionals hold more shares of PMN or IPSC?

Does the media favor PMN or IPSC?

Which has more risk and volatility, PMN or IPSC?

Which has better valuation and earnings, PMN or IPSC?

Is PMN or IPSC more profitable?

Summary

How does Promis Neurosciences compare to X4 Pharmaceuticals?

Does the media prefer XFOR or PMN?

Do analysts rate XFOR or PMN?

Which has stronger valuation and earnings, XFOR or PMN?

Is XFOR or PMN more profitable?

Which has more risk & volatility, XFOR or PMN?

Do insiders and institutionals have more ownership in XFOR or PMN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMN vs. The Competition

Promis Neurosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools